BEYONTTRA
Live / Allowed — First extension granted (statement of use) (as of 30 Sept 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 25 Sept 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99413643
- Mark type
- Word mark
- Filed
- 25 Sept 2025
- Published for opposition
- 24 Feb 2026
- Attorney of record
- Joyce M. Ferraro
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals for use in the treatment of oncological, cardiological, dermatological, neurological, genetic, orthopedic and metabolic diseases and disorders
Owner
- BridgeBio Pharma, Inc., Palo Alto, CA, US
- BridgeBio Pharma, Inc., Palo Alto, CA, US
Prosecution history
- 30 Sept 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 30 Sept 2026 — SOU EXTENSION 1 GRANTED
- 30 Sept 2026 — SOU EXTENSION 1 FILED
- 30 Sept 2026 — SOU TEAS EXTENSION RECEIVED
- 15 Sept 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 15 Sept 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 15 Sept 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 15 Sept 2026 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 15 Sept 2026 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 21 Apr 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 24 Feb 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 24 Feb 2026 — PUBLISHED FOR OPPOSITION
- 18 Feb 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 02 Feb 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 02 Feb 2026 — ASSIGNED TO EXAMINER